QDEL
What one share of Quidelortho holds
In Vitro and In Vivo Diagnostic Substances
Our vision is to advance diagnostics to power a healthier future. With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity for clinicians and patients to help create better health outcomes.
Quidelortho’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-28; the balance sheet is as of 2026-06-28.
| Sales | $39.27 |
|---|---|
| Profit | −$15.39 |
| Capex (buildings and equipment) | $2.26 |
| Free cash flow | −$3.10 |
| Cash and investments | $1.81 |
| Debt | $37.12 |
| Book value | $25.99 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $38.11 | $18.59 | $1.49 | $12.95 | — | $31.66 |
| 2021 | $39.59 | $16.41 | $6.83 | $11.96 | — | $46.27 |
| 2022 | $56.90 | $9.56 | $2.45 | $12.97 | — | $74.32 |
| 2023 | $44.88 | −$0.15 | $3.13 | $1.06 | — | $75.05 |
| 2024 | $41.41 | −$30.54 | $2.90 | −$1.67 | — | $44.35 |
| 2025 | $40.27 | −$16.69 | $2.78 | −$1.22 | — | $28.28 |